Navigation Links
FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia
Date:5/6/2009

ROCKVILLE, Md., May 6 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that the US Food and Drug Administration (FDA) has granted marketing approval of Fanapt(TM) (iloperidone) for the acute treatment of adult patients with schizophrenia. The approval was supported by two placebo-controlled Phase III clinical studies comparing Fanapt(TM) to placebo and active control in patients with schizophrenia, as well as safety data from more than 3,000 patients.

Fanapt(TM) is a mixed dopamine D2 / serotonin 5HT2A receptor antagonist, and belongs to the class of atypical antipsychotics.

"The approval of Fanapt(TM) marks a new opportunity for many patients with schizophrenia, who experience only partial responses to current therapies, to achieve better control of their symptoms," remarked Dr. Peter J. Weiden, Professor of Psychiatry and Director of the Psychotic Disorders Program at the University of Illinois at Chicago. "Having Fanapt(TM) available is a major help for our patients in offering an effective antipsychotic with an excellent side effect profile across a wide range of major tolerability problems associated with other antipsychotic therapies."

The efficacy of Fanapt(TM) for the treatment of schizophrenia was supported by two placebo-controlled short-term (4- and 6-week) trials. Both trials enrolled patients who met the DSM-III/IV criteria for schizophrenia, and Fanapt(TM) was shown to be superior to placebo in controlling symptoms of schizophrenia across doses of 12mg to 24mg per day. The recommended target dose range of Fanapt(TM) is 12mg to 24 mg per day. Titration to the target dose of 12mg per day can be achieved in 4 days.

Vanda plans to make Fanapt(TM) available in pharmacies later this year.

"Fanapt(TM) is an important option for
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
2. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
3. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
4. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
5. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
6. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
7. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
8. FDA Approves First Hepatitis B Viral Load Test
9. U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinsons Disease
10. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
11. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... July 30, 2014  DigiPath, Inc. (OTCBB and OTCQB: ... into the cannabis testing and education markets, announced today ... and affairs not previously disclosed or, to its knowledge, ... market action. "We have noticed unusual price ... three trading days," said Steve Barbee , CEO ...
(Date:7/30/2014)... Coordinators, Inc. (PCI) is pleased to announce it has ... Limited (Penn Pharma). Penn Pharma is headquartered in Tredegar, ... Kingdom and operates regional offices in ... Tokyo , Japan. Penn Pharma offers both drug development ... manufacturing, as well as Clinical Packaging, Labeling, and global ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
... 19, 2011 Families of Spinal Muscular Atrophy announced today ... and Drug Administration to commence a Phase I safety study ... being developed for Spinal Muscular Atrophy. FSMA ... stages of drug development, when risk is the highest.  It ...
... PRNewswire / -- Silicon Valley Bank ... companies worldwide, released a study today that ... capital-backed biotech and medical device companies. Based ... of US venture-capital backed companies (60 biotech and 58 ...
Cached Medicine Technology:Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA 2Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA 3Venture-Backed Biotech Generates Quicker Exits but Lower Multiples than Medical Device 2Venture-Backed Biotech Generates Quicker Exits but Lower Multiples than Medical Device 3
(Date:7/30/2014)... July 30, 2014 Good Neighbor ... in an upcoming episode of Innovations with Ed ... Channel. Dates and show times TBA. , In ... Neighbor Community Services’ vision to redefine the traditional ... and dynamic services. Through passion, innovation, determination, excellence, ...
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- It can happen ... television, dresser or computer monitor and gets critically injured ... of a young child should look around their homes and ... a child. Imagining it is better than it becoming a ... Emergency Physicians, said in a college news release. Between ...
(Date:7/30/2014)... as well as evolutionary changes in a living organismhad ... throughout the genome. , However, recent studies have shown ... mutations that arise simultaneously and in close proximity to ... found in regions where chromosomal rearrangements take place. , ... , may one day lead to new cancer therapies, ...
(Date:7/30/2014)... July 30, 2014 Visitors to our ... over $8,500 to ensure its protection. Bob Kiesendahl, one ... check to the Delaware Highlands Conservancy for donations collected ... small $2-per-stay donations add up fast, as visitors welcome ... Upper Delaware River Region. , The Kiesendahl family has ...
(Date:7/30/2014)... 2014) The phrase "we caught it early" is possibly ... midst of a cancer diagnosis. Combating cancer in its ... certain part of the body, gives patients the best ... colon, prostate and other forms of cancer are touted ... providers recommend cancer screenings as a precautionary measure, especially ...
Breaking Medicine News(10 mins):Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:Tip-Over Furniture Can Kill Kids 2Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3
... July 8 Fate Therapeutics, Inc. ... research on small molecule modulators of the Wnt pathway ... International Society for Stem Cell Research (ISSCR) in Barcelona, ... selected Wnt activators induce the differentiation of mesenchymal stem ...
... ... a name change to Freedom Disability and has expanded its operations into a new corporate ... growth of the business, bringing hundreds of new jobs to the state. , ... Shelton, CT (PRWEB) July 8, 2009 -- ...
... , HUNTINGTON BEACH, Calif., July 8 "You are what you ... what you drink may be as important as what you eat ... and many others, according to Dr. Cheryle Hart, medical advisor for ... . , , One study referred ...
... ... according to Ed Sinson, On-line Forum and Social Networking Representative. , ... Irvine, Calif. (Vocus) July 8, 2009 ... according to Ed Sinson, On-line Forum and Social Networking Representative. , , ,"We ...
... ... Parts Washers are growing in popularity. These parts washers are cost effective and quick ... economic climate. , ... (Vocus) July 8, 2009 -- Midbrook, a Jackson, MI based manufacturer of industrial parts ...
... created using embryonic stem cells for the first time in ... understanding of the causes of infertility. Researchers led ... England Stem Cell Institute (NESCI) have developed a new technique ... the laboratory. The work is published today (8th ...
Cached Medicine News:Health News:Fate Therapeutics to Present Data on Stimulation of Osteogenic Activity Using Small Molecule Modulators of Wnt Pathway 2Health News:National Social Security Disability Advocacy Firm Changes Name to "Freedom Disability" and Acquires 22,000 Square Foot Corporate Headquarters in Shelton, CT 2Health News:National Social Security Disability Advocacy Firm Changes Name to "Freedom Disability" and Acquires 22,000 Square Foot Corporate Headquarters in Shelton, CT 3Health News:Latest Studies Show 'Junk Drinks' Pose as Many Health Threats as 'Junk Food' According to AquaHydrate Medical Advisor 2Health News:Latest Studies Show 'Junk Drinks' Pose as Many Health Threats as 'Junk Food' According to AquaHydrate Medical Advisor 3Health News:Latest Studies Show 'Junk Drinks' Pose as Many Health Threats as 'Junk Food' According to AquaHydrate Medical Advisor 4Health News:Bariatric Advantage Participates in Social Networks 2Health News:Refurbished and Used Industrial Parts Washers Grow in Popularity 2Health News:Human sperm created from embryonic stem cells 2
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Medicine Products: